Wall Street is mulling Intra-Cellular Therapeutics Inc.’s chances of replicating with Caplyta (lumateperone) the path followed by Abbvie Inc. with Vraylar (cariprazine) in major depressive disorder (MDD), and possibly overtaking the latter in the difficult indication. Read More
Coming off a presentation at the European Alliance of Associations for Rheumatology meeting, where a single report of disease recurrence in a lupus patient overshadowed promising early data for Kyverna Therapeutics Inc.’s autoimmune candidate, KYV-101, the Emeryville, Calif.-based company rallied on news of a case report describing the first use of the CD19-targeting CAR T-cell therapy in a patient with stiff-person syndrome, a rare, progressive neurological autoimmune disorder for which there is limited treatment. Read More
The annual Companies to Watch report, which was just released, looks closely at seven companies flying under the radar that are developing antibody-drug conjugates (ADCs) for treating cancer. Companies examined in the new report are Adcendo ApS, Araris Biotech AG, Go Therapeutics Inc., Heidelberg Pharma AG, Pheon Therapeutics Ltd., Tallac Therapeutics Inc. and Tubulis GmbH. Read More
Preliminary data show Biotron Ltd.’s lead compound BIT-225 met the primary objectives of the phase II BIT225-011 trial, a longitudinal, open-label trial designed to characterize the effect of the compound added to ongoing, suppressive antiretroviral therapy in HIV-1-infected, treatment-experienced patients who achieved only partial immune reconstitution. Read More
During the basic science morning track on the last day of this year’s Annual Congress of the European Hematology Association (EHA), the attention was focused on oncogenic transcription factors and complexes considered turning points within the acute myeloid leukemia (AML) arena. Read More
The adverse effects of PD-1 blockers on the CNS observed in cancer patients could occur through their effects on an enzyme that activates microglia. Pharmacological inhibition of the enzyme in mice reduced microglial activation and cognitive deficit without altering the antitumor capacity of the immunotherapy. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Celon, Cel-Sci, Clene, Clover, Intra-Cellular, Kyverna, Mitsubishi Tanabe, Taysha Gene Therapies, TME. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Altus, Alvotech, Advanz, Dermtech, Hikma, Iktos, Ionis, Italfarmaco, Otsuka, Spektar, Xellia. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Bavarian Nordic, Bridgebio, Junshi, Kalvista, Merck & Co., Pyros, Zentalis. Read More
